Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MESO vs MGNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MGNX Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

MGNX Overall Winner 6-Pillar Tally: MESO 3 – 3 MGNX Matrix Metrics: MESO 4 – 6 MGNX

As of Nov 16, 2026, MacroGenics, Inc. (MGNX) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). MESO carries a Unified Composite Score of 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas MGNX carries 43.6/100 (HOLD) at $2.02 (61.0x Forward P/E, -21.7% operating margin).

  • Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3); meanwhile MGNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MESO vs MGNX
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
35.5 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $13.64 · SMA50: $14.22
MGNX NASDAQ Head-to-Head Winner
MacroGenics, Inc.
Pharmaceutical Preparations
$2.02
-7.95% 1D
Market Cap $145.9M
TTM Revenue $175M
Forward P/E 61.0x
Beta / 30D Vol 1.37β · 148% Vol
Unified Composite Score
43.6 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.4%), weak momentum, RSI 28
RSI-14: 28.5 · SMA20: $2.50 · SMA50: $3.28

6-Pillar Scorecard Institutional Category Breakdown (MESO 3 – 3 MGNX)

Columns: Metric · MESO · MGNX
1. Valuation Multiples MGNX
Forward P/E N/M 61.0x
Trailing P/E N/M 61.0x
PEG Ratio N/M 0.01x
EV / Revenue 14.1x 0.4x
2. Growth & Scale MESO
Revenue Growth (YoY) +390.7% +378.0%
Earnings Growth (YoY) +0.0% -70.4%
TTM Revenue (USD) $120M $175M
Market Cap $1.7B $145.9M
3. Profitability & Quality MGNX
Gross Margin 80.0% -0.7%
Operating Margin -42.6% -21.7%
Net Profit Margin -47.8% -8.3%
Return on Equity (ROE) -9.9% -225.9%
4. Balance Sheet & Cash Flow MESO
Cash Generation (TTM) -$45M EBITDA -$66M
Cash Flow Margin -37.1% EBITDA Mgn -37.4%
Net Cash / Leverage $4.38 Book/Sh · -9.9% ROE $79M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MESO
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 76.8% (37th %ile) 52.8% (1st %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat MGNX
OpEx & R&D Intensity N/A 21.0% of Rev ($37M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MESO (4) vs MGNX (6)
Institutional Metric MESO MGNX Criterion Row Edge
Market Capitalization
Scale
$1.7B $145.9M Larger Scale MESO
Trailing P/E Ratio
Valuation
N/M 61.0x Lower Multiple MGNX
Forward P/E Ratio
Valuation
N/M 61.0x Lower Multiple MGNX
Revenue Growth (YoY)
Growth
+390.7% +378.0% Higher Growth MESO
Operating Margin (TTM)
Profitability
-42.6% -21.7% Higher Margin MGNX
Net Profit Margin
Profitability
-47.8% -8.3% Higher Margin MGNX
Return on Equity (ROE)
Capital Efficiency
-9.9% -225.9% Higher ROE MESO
52-Week Range Position
Momentum
6% ($12–$22) 19% ($1–$5) Stronger Trend MGNX
Beta / 30D Volatility
Risk Regime
1.18β · 78% Vol 1.37β · 148% Vol Lower Realized Risk MESO
Unified Institutional Score
Composite Signal
35.5 / 100 (SELL) 43.6 / 100 (HOLD) Higher Composite MGNX
Trailing 12M Revenue (USD)
Operating Scale
$120M $175M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
80.0% -0.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.1x EV/Rev 0.01x PEG · 0.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) -$66M ($79M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MESO +31.59 pp
MESO: -6.1% · MGNX: -37.69%
3M Horizon MESO +25.3 pp
MESO: -25.19% · MGNX: -50.49%
6M Horizon MESO +38.63 pp
MESO: -14.82% · MGNX: -53.45%
1Y Horizon MGNX +42.98 pp
MESO: -16.42% · MGNX: +26.56%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MESO vs MGNX. Trailing 12-month operating profitability (MESO -42.6% vs MGNX -21.7%) and valuation multiples (MESO N/M vs MGNX 61.0x Forward P/E) are benchmarked directly in Pillar 4 below.

MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M
MGNX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$175M
Gross Margin-0.7%
Op. Margin-21.7%
ROE / Fwd P/E-225.9% · 61.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MGNX BREAKDOWN
122d in phase · OBV NEUTRAL
Current IV 52.8%
IV Percentile 1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact MGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $145.9M market capitalization and -21.7% operating margin.
OpEx & R&D Reinvestment 21.0% of Rev ($37M)
90D Engineering Disclosures 0 Published

Investor FAQ MESO vs MGNX Key Questions & Quantitative Answers

As of Nov 16, 2026, MacroGenics, Inc. (MGNX) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, R&D & Supply-Chain Moat). MESO carries a Unified Composite Score of 35.5/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin), whereas MGNX carries 43.6/100 (HOLD) at $2.02 (61.0x Forward P/E, -21.7% operating margin). Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.3); meanwhile MGNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 28.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MESO leads the Growth & Scale pillar: MESO posts +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin), compared with MGNX at +378.0% YoY revenue growth and -70.4% YoY earnings growth on $175M TTM revenue (-0.7% gross margin, -21.7% operating margin). On trailing 12-month operating scale, MESO generates $120M in USD-normalized revenue versus $175M for MGNX. In operating R&D and SG&A reinvestment, MESO deploys N/A (0 90-day corporate R&D disclosures) versus 21.0% of Rev ($37M) (0 disclosures) for MGNX.

MGNX screens cheaper on headline valuation multiples. MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin), whereas MGNX trades at 61.0x Forward P/E, 61.0x Trailing P/E, 0.01x PEG, and 0.4x EV/Revenue (-37.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MESO (-9.9% ROE) versus MGNX (-225.9% ROE) capital efficiency.

In options market volatility and institutional positioning, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk). By comparison, MGNX carries 52.8% implied volatility (1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.37β · 148% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.